About Basking Biosciences

Richard Shea

CEO

Mr. Shea joined Basking Biosciences as CEO shortly after its founding in 2019. He is an experienced life sciences entrepreneur and has been involved in the creation and growth of multiple life science start-up and growth companies for over the last 20 years. He began his career at Merck. Rich received his MBA from Duke and his B.S. from the University of Notre Dame. Prior to attending Duke, Rich served for 5 years as a Submarine Officer in the U.S. Navy.

Prof. Bruce Sullenger, PhD

Founder, Scientific Advisor

Professor Sullenger is the Joseph W. And Dorothy W. Beard Distinguished Professor of Experimental Surgery and the Founding Director of the Translational Research Institute at Duke University. Professor Sullenger is a globally recognized expert in RNA biology. Over the last 20 years, his research has been focused on the generation and clinical translation of RNA aptamers that block proteins involved in cardiovascular diseases and immune modulation. Professor Sullenger has over 25 issued U.S. patents related to RNA therapeutics.

Shahid Nimjee, MD, PhD

Founder, Chief Medical Officer

Shahid Nimjee, MD, PhD is an Associate Professor and a practicing neurosurgeon at The Ohio State University Wexner Medical Center (OSUWMC) where he treats stroke patients. Dr. Nimjee also leads a basic research laboratory at OSUWMC that is focused on evaluating anti-vWF aptamers and their antidotes to treat thromboembolic stroke. At Basking, Dr. Nimjee serves as the Company’s Interim CMO responsible for leading preclinical research activities at his laboratory at OSUWMC and designing the clinical trial plan for DTRI-031 and DTRI-025. Shai received his undergrad degree from Yale and his MD and PhD degrees from Duke.

Meet Shahid Nimjee, MD, PhD

Leo Pavliv, R.Ph.

CMC Lead

Mr. Pavliv is a seasoned drug developer with over 30 years of experience developing pharmaceutical and biological products. He is a Principal at PharmDev Consulting and is leading Basking’s CMC activities, including vendor selection and oversight. Mr. Pavliv has been responsible for more than 100 IND submissions and amendments, clinical trial agreements (CTAs), clinical trial exemptions (CTXs) and more than a dozen marketing and supplemental applications. Mr. Pavliv received an MBA and BS in Pharmacy from Rutgers University.

Dr. Michael Hill

Clinical Trial Advisor

Dr. Michael Hill is a Professor for the Departments of Clinical Neurosciences, Community Health Sciences, Medicine and Radiology at the University of Calgary and Director of the Stroke Unit for the Calgary Stroke Program, Alberta Health Services. Dr. Hill’s research interests include stroke thrombolysis, stroke epidemiology, and surveillance and clinical trials. He is currently leads the largest ongoing Phase 3 trial in ischemic stroke.

Stacy Nelson

Head, Program Manager

Drug Development Professional with over 25 years’ experience managing multidisciplinary projects involving regulatory, Phase 1-3 clinical trials, CMC, and post-marketing pharmacovigilance according to GCP, GMP and ICH regulations.  Direct experience in the preparation and attendance at regulatory agency meetings; preparation of Investigational New Drug Applications (INDs) and 6 New Drug Applications (NDAs); and initiation and management of over 25 Phase 1 and Phase 2 multicenter clinical trials spanning the therapeutic areas of oncology, blood products, COVID-19, metabolism, gene transfer in cardiovascular diseases and neurology.